A high-throughput platform has been developed to create lipid nanoparticles capable of delivering mRNA and CRISPR-Cas9 gene editing tools effectively to the lungs via intratracheal administration, expanding the potential clinical applications of gene editing and mRNA-based technologies.
The ability to create in vivo genomic medicines for tissues other than the liver has been impeded by difficulties in delivery. Using a high-throughput platform, we developed lipid nanoparticles that can effectively deliver mRNA and CRISPR-Cas9 gene editing tools to the lungs through intratracheal administration, expanding the potential clinical uses of gene editing and mRNA-based technologies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据